We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Jennifer Ho

Jennifer E. Ho MD

Associate Professor of Medicine, Harvard Medical School; Advanced Heart Failure and Heart Transplantation, Cardiology Division, Massachusetts General Hospital, Boston, Massachusetts

Dr. Ho is an Associate Professor at Harvard Medical School and faculty member of the Advanced Heart Failure and Cardiac Transplantation section and the Cardiovascular Research Center at MGH. She is a nationally recognized independent investigator and her laboratory is focused on clinical and translational research to understand mechanisms driving heart failure with preserved ejection fraction (HFpEF). Specifically, her laboratory is focused on obesity-related changes that may lead to HFpEF, including inflammation and metabolic dysfunction. She has published over 80 peer-reviewed original investigations and is the recipient of multiple NIH awards and the MGH Claflin Distinguished Scholar Award.

She plays an active role in the education of both residents and fellows and has mentored over 15 trainees in her laboratory. Dr. Ho has served as the Cardiology Subspecialty Core Educator to the MGH Medicine Residency program and is currently Associate Program Director of the Cardiovascular Medicine Fellowship at MGH. She is the 2018 recipient of both the inaugural MGH Medicine Residence Excellence in Mentoring Award and the Brian McGovern Memorial Teaching Award.

Disclosures

Dr. Ho has no relevant disclosures.

Recent Contributions to PracticeUpdate:

  1. Efficacy and Safety of Dapagliflozin in People With HFrEF